CARLSBAD, Calif., Oct. 26 /PRNewswire-FirstCall/ -- iVOW, Inc. , today announced that it has received a letter from the Nasdaq Capital Market advising that the Company has regained compliance with Marketplace Rule 4310(c)(4), relating to the maintenance of a minimum closing bid price of $1.00 per share or greater for at least 10 consecutive trading days.
The Company also continues to be in compliance with the Shareholders’ Equity requirement of the Nasdaq Capital Market and is now in full compliance with all continued listing requirements for the exchange.
iVOW effected a one-for-ten reverse stock split on October 10, 2005. iVOW’s shares trade under the symbol “IVOWD”. The “D” is a temporary indicator of the reverse stock split and will be removed from the ticker symbol after 20 trading days following the reverse split.
iVOW
Our business is focused exclusively on the disease state management of chronic and morbid obesity. We provide program management, operational consulting and clinical training services to physicians and hospitals involved in the medical and surgical treatment of morbidly obese patients. We also provide specialized vitamins to patients who have undergone obesity surgery. Our corporate website is www.ivow.com; information on our nutritional supplements for post-surgical gastric bypass patients may be found on www.vistavitamins.com. iVOW is the new corporate name of Vista Medical Technologies, Inc. iVOW is traded on the NASDAQ Capital Market under the stock symbol IVOWD.
Forward Looking Statements
This news release may contain forward-looking statements concerning the business and products of iVOW. Actual results may differ materially depending on a number of risk factors, including, but not limited to the following: the successful closing of the acquisition of Sound Health Solutions; the successful integration of the SHS business; our ability to penetrate the market for obesity surgery management services; customer acceptance of our products and services; decisions by Medicare and carriers to provide coverage for bariatric surgical procedures; uncertainties related to our healthcare services business model; and our efforts to maintain compliance with the continued listing requirements of the Nasdaq Capital Market. Other risks inherent in our business are described in our Securities and Exchange Commission filings, including our Annual Report on Form 10-K for the year ended December 31, 2004, as amended, and our most recent quarterly report on form 10-Q. We undertake no obligation to revise or update any forward-looking statements to reflect events or circumstances after the date of this release.
AT iVOW: Michael H. Owens, MD, MPH, FACPE, CPE President & CEO mowens@ivow.com (760) 603-9120 AT FINANCIAL RELATIONS BOARD: Tony Rossi Media Contact trossi@financialrelationsboard.com (310) 854-8317
iVOW, Inc.
CONTACT: Michael H. Owens, MD, MPH, FACPE, CPE, President & CEO of iVOW,Inc., +1-760-603-9120, mowens@ivow.com; or media, Tony Rossi of FinancialRelations Board, +1-310-854-8317, trossi@financialrelationsboard.com, foriVOW, Inc.
Web site: http://www.ivow.com/
